Amarin Expands REDUCE-IT Data at ESC 2026, Reinforcing Cardiovascular Risk Reduction — Amarin Corporation plc

Event summary

Amarin presented new REDUCE-IT data at ESC Congress 2026, highlighting insights on treatment adherence, long-term outcomes, and mechanistic pathways of icosapent ethyl (IPE).
2026 ESC/ERA guidelines reinforced clinical evidence supporting IPE for cardiovascular risk reduction in patients with chronic kidney disease.
Post-hoc analyses explored lipoprotein(a) variability, sex differences in treatment persistence, and effects of IPE on coagulation biomarkers.
Mechanistic studies showed EPA reduces oxidation of lipoprotein(a) and alters endothelial cell protein expression, potentially contributing to clinical benefits.

The big picture

Amarin's ESC 2026 presentations underscore the growing body of evidence supporting icosapent ethyl as a complementary therapy for reducing cardiovascular risk. The inclusion of REDUCE-IT data in ESC/ERA guidelines further solidifies its role in managing patients with chronic kidney disease, a population with substantial residual risk. The mechanistic insights and post-hoc analyses position Amarin to differentiate its product in a competitive cardiovascular market, where residual risk remains a critical unmet need.

What we're watching

Clinical Evidence Expansion: How the new REDUCE-IT data will influence prescribing patterns and payer coverage for icosapent ethyl in high-risk cardiovascular patients.
Mechanistic Insights: Whether the mechanistic studies on EPA's effects on lipoprotein(a) oxidation will accelerate development of targeted therapies for residual cardiovascular risk.
Treatment Adherence: The pace at which Amarin addresses sex-related differences in treatment persistence to optimize long-term outcomes in cardiovascular clinical trials.